Home » Posts tagged with » Gene therapy company
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]

Astellas Pharma to acquire US gene therapy company Audentes Therapeutics

Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]

Continue reading …
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy

Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy. Currently, nadofaragene firadenovec is in late-stage development for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). […]

Continue reading …
Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma

Cellectis said that it has dosed the first patient in a phase 1  study – the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf CAR-T product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM). The French gene therapy company began the phase 1 dose-escalation study after getting clearance from the US Food […]

Continue reading …
Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease

US gene therapy company Avrobio has secured orphan-drug designation for AVR-RD-02, its investigational gene therapy, for the treatment of Gaucher disease, from the US Food and Drug Administration (FDA). AVR-RD-02 is made up of the patient’s own hematopoietic stem cells, which are modified genetically to express glucocerebrosidase (GCase), an enzyme that is deficient in Gaucher […]

Continue reading …
Castle Creek to acquire cell and gene therapy company Fibrocell

Castle Creek acquisition of Fibrocell : Castle Creek Pharmaceutical Holdings (CCP Holdings) has agreed to acquire Fibrocell Science, a cell and gene therapy company engaged in developing autologous cell-based therapies for skin and connective tissue disorders. Financial terms of the deal were not disclosed, as per the latest pharma industry news. CCP Holdings is a […]

Continue reading …
US gene therapy company Renovacor raises $11m for BAG3 gene therapy

US gene therapy company Renovacor, which is engaged in developing BAG3 gene therapy and other gene therapies for cardiovascular disease, has raised $11 million through a Series A financing round led jointly by Novartis Venture Fund, Broadview Ventures, and BioAdvance. New Leaf Venture Partners and Innogest Capital also joined the Series A funding round. The […]

Continue reading …
Apic Bio bags FDA orphan designation for ALS SOD1 gene therapy APB-102

US gene therapy company Apic Bio said that APB-102, its ALS SOD1 gene therapy, has been granted orphan drug designation by the US Food and Drug Administration (FDA). APB-102 is expected to shortly enter into clinical development for the genetic disorder – SOD1 amyotrophic lateral sclerosis (ALS). The orphan designation is given to novel drugs […]

Continue reading …
Biogen to acquire UK gene therapy company Nightstar Therapeutics for $800m

Biogen acquisition of Nightstar Therapeutics : US biotech company Biogen has signed a deal of $800 million to acquire Nightstar Therapeutics, a British clinical-stage gene therapy company, as per the latest pharma acquisition news. Nightstar Therapeutics primarily focuses on the developing adeno-associated virus (AAV) treatments for inherited retinal disorders. Biogen acquisition of Nightstar Therapeutics According […]

Continue reading …
Roche in $4.3bn deal to buy gene therapy company Spark Therapeutics

Roche acquisition of Spark Therapeutics : Swiss pharma giant Roche has signed an all-cash deal worth $4.3 billion to acquire US gene therapy company Spark Therapeutics, as per the latest pharma acquisition news. Roche acquisition of Spark Therapeutics According to the merger terms, Roche will offer to buy 100% of Spark Therapeutics for $ 114.50 […]

Continue reading …
Page 1 of 212